Search
BioLine RX Ltd
BLRXAdd to Watchlist
1.990USD
-0.030-1.49%
Close 10-30 16:00（ET）
9.91MMarket Cap
LossP/E TTM
BioLine RX Ltd (BLRX) Stock Price Target & Forecast
Analyst Rating
Based on 1 analysts giving stock ratings to BioLine RX Ltd in the past month.
Buy
0 Strong Buy
1 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
22.000USD+1000.00%
BLRX Analyst Recommendation Trends
In the current month, BLRX has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BLRX average Analyst price target in the last month is 22.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
0
0
0
0
0
0
0
0
1
1
0
1
1
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
1
1
2
2
2
BLRX Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
11
8
0
0
23
Financial Forecasting
Based on analysts' estimates, BLRX EPS is projected to reach -0.385 in FY2026Q3, following reported EPS of -0.684 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q3
FY2025Q4
FY2026Q2
FY2026Q1
FY2026Q3
FY2026Q4
Forecast
--
-0.77
-0.49
-0.29
-0.39
-0.40
Actual
-0.22
-0.50
-0.68
--
--
--
Surprise
--
+34.55%
-39.59%
--
--
--
FAQs
What is BioLine RX Ltd's expected revenue for the next quarter?
BioLine RX Ltd's expected revenue is 357.50K.
What is BioLine RX Ltd's price target?
Analysts forecast that BioLine RX Ltd's price target is USD 22.00, with the highest forecast at USD 26.00 and the lowest forecast at USD 18.00.
How have BioLine RX LtdBLRX's recent earnings per share performed?
The market expectation was USD -0.68, while BioLine RX LtdBLRX's earnings per share (EPS) for the previous quarter was USD -0.50. EPS for the next quarter is expected at USD -0.39.
What is the analyst rating for BioLine RX Ltd?
Based on the ratings of BioLine RX Ltd's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.